

SURGIFLO® Haemostatic Matrix Kit versus FLOSEAL

SURGIFLO® stops bleeding before FLOSEAL is ready to use¹⁻⁴

When faced with bleeding situations, surgeons need a hemostatic matrix that is easy to prepare, offers reliable viscosity, and is safe and effective.

Compared to FLOSEAL, SURGIFLO® offers these advantages:

- Ready to use 2 minutes faster^{1-3*}
- Maintains better uniform viscosity^{5†}



	SURGIFLO®	FLOSEAL	SURGIFLO® Advantage
PREPARATION			
Overall preparation time ⁶	Faster	Slower	Product is ready for use over two minutes faster than FLOSEAL¹⁻³
Thrombin reconstitution time (avg.) ³	13 seconds (8 mL)	102 seconds (5 mL) 136 seconds (10 mL)	Significantly faster thrombin reconstitution
30 second gelatin rehydration required ^{1,2}	No	Yes	Premoistened gelatin means no need to wait 30 seconds after mixing^{1,5,7}
CONSISTENCY			
Uniform viscosity throughout the syringe and over time ⁵	Less variability	More variability	More uniform consistency for a more predictable response during application
EFFICACY & SAFETY			
Time to haemostasis (includes oozing, flowing, spurting blood) ⁴	< 1 minute [‡]		No significant difference
Safety ⁸	Same		No significant difference
Indications for Use ⁶	Same		No significant difference
SPECIFICATIONS			
Available with and without thrombin	Yes	No	Resource and cost saving opportunity for specialties that already have thrombin on hand
Available sizes	8 mL	5 mL/10 mL	Simplifies ordering with just one SKU

*Compared to 10 mL FLOSEAL Haemostatic Matrix.

[†]Based on in vitro viscosity testing of SURGIFLO® 8 mL and FLOSEAL Hemostatic Matrix 5 mL; each product was prepared following Instructions for Use.

[‡]In animal models.

The third-party trademarks used herein are trademarks of their respective owners.

SURGIFLO® Hemostatic Matrix



References: 1. SURGIFLO Hemostatic Matrix Kit (2994). Instructions for Use. Ethicon, Inc. Somerville, NJ. 2. FLOSEAL Hemostatic Matrix, Instructions for Use. Baxter Healthcare. 3. Comparison of thrombin reconstitution time in SURGIFLO Hemostatic Matrix Kit vs. FLOSEAL Hemostatic Matrix. 11052017. Ethicon, Inc. 4. Langkilde, S. Evaluation of the dose response curve for Hemostatic Efficacy of Surgiflo Next Generation mixed with Thrombin. 2013 Report NG-162. Ethicon, Inc. 5. Wang, A. Measurements of Viscosity and Thrombin Activity of SURGIFLO 2993 as Compared to FLOSEAL Over Time. Technical Report, April 7, 2013. Ethicon, Inc. 6. Time Motion Study Statistical Summary, Felton Willis; July 13, 2015. Ethicon, Inc. 7. SURGIFLO® Technical Report, 2017. Ethicon, Inc. 8. Valls M, Almazan R, Fernandez R, et al. Systematic Revision and Meta-Analysis of Hemostatic Matrices for Bleeding Control. 2016 Poster.

Johnson & Johnson Medical Pty Ltd. 1-5 Khartoum Rd. North Ryde, NSW 2113
Johnson & Johnson (NZ) Ltd. 507 Mt. Wellington Hwy, Mt. Wellington, Auckland 1060
ANZ 166018-210131